Annual Financial Statement Archives

Interim Report Fourth Quarter 2023

October-December 2023, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -54,513 thousand (-55,220) Earnings per share before dilution amounted to SEK -1.85 (-2.48) Cash flow from operating activities amounted to SEK -32,626 thousand (-35,003) Cash flow from investing activities amounted to SEK -20,729 thousand (-29,481) January-December 2023, Group […]

Interim Report Fourth Quarter 2022

October–December 2022, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -55,220 thousand (-51,944) Earnings per share before dilution amounted to -2.48 SEK (-2.62) Cash flow from operating activities amounted to SEK -35,003 thousand (-10,280) Cash flow from investing activities amounted to SEK -29,481 thousand (-33,691) January–December 2022, Group […]

Xspray Pharma publishes Q4 Year-End report 2021

”When looking back at Xspray Pharma’s fourth quarter 2021, I see it marked by hope for the future. After the end of the quarter, we reached a significant milestone when the US Food and Drug Administration (FDA) announced that it had agreed to review Xspray Pharma’s first product candidate: Dasynoc, an improved version of dasatinib. […]

Xspray Pharma publishes Interim report Q4, January – December 2020

“Our business model is different from traditional drug development. Instead of developing a new drug candidate that will have to undergo Phase I, Phase II and Phase III studies, our technology platform produces amorphous PKI versions that need to demonstrate bioequivalence with already marketed drugs. Several of the marketed PKI:s are highly variable and have […]

Xspray Pharma publishes Interim report Q4, January – December 2019

PRESS RELEASE February 28, 2020 “One important milestone was reached in June when our production facility in Italy was completed and was able to do a test run. We have now proven that our technology is possible to scale up – and we are the first in the world to manufacture amorphous material in the […]

Xspray Pharma publishes its Year-end Report, January – December 2018

”Following determined efforts, we demonstrated performance in 2018 that has brought us significantly closer to a market launch of HyNap-Dasa and have thus increased Xspray’s possibilities of building shareholder value.” Per Andersson, CEO Xspray Pharma AB (publ) Fourth quarter, October – December 2018, parent company Amounts in brackets refer to the corresponding period for the […]